Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka announces positive trial data for new dry eye therapy

Otsuka announces positive trial data for new dry eye therapy

13th May 2011

Otsuka has announced positive data from a new phase III clinical trial of a new developmental therapy for sufferers of dry eye.

The company recently conducted a study involving 188 patients in Japan for rebamipide ophthalmic suspension, which aimed to compare its performance against a sodium hyaluronate solution among patients with signs and symptoms of dry eye.

Results revealed at the Association for Research in Vision and Ophthalmology meeting this month showed that Otsuka's drug proved non-inferior in terms of its performance in reducing levels of corneal-conjunctival damage.

It was also shown to perform better than the alternative in relieving symptoms such as foreign body sensation and eye pain.

Otsuka is now filing for regulatory approval of the drug in its native Japan, while clinical development of the therapy remains ongoing in other territories.

Earlier this year, the company made a donation of medical products to aid victims of the March 2011 earthquake in Japan, which damaged a number of Otsuka facilities.ADNFCR-8000103-ID-800531618-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.